<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pitavastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08860</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Pitavastatin a lipid-lowering agent that belongs to the statin class of medications for treatment of dyslipidemia. It is also used for primary and secondary prevention of cardiovascular disease. <span class="caps">FDA</span> approved in Aug 3, 2009.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08860/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08860/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08860.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08860.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08860.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08860.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08860.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08860">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Pitavastatin Calcium </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000140/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000140/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: RHGYHLPFVJEAOC-FFNUKLMVSA-L</li>
              <li>Monoisotopic Mass: 880.284814023</li>
              <li>Average Mass: 880.984</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000140">DBSALT000140</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Livalo </td><td>Kowa Pharmaceuticals America, Inc. </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypolipidemic-agents">Hypolipidemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>147511-69-1</td></tr><tr><th>Weight</th><td>Average: 421.4608<br>Monoisotopic: 421.168936466</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>24</sub>FNO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>VGYFMXBACGZSIL-MCBHFWOFSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Quinolines and Derivatives</td></tr><tr><th>Subclass</th><td>Phenylquinolines</td></tr><tr><th>Direct parent</th><td>Phenylquinolines</td></tr><tr><th>Alternative parents</th><td>Phenylpyridines; Beta Hydroxy Acids and Derivatives; Fluorobenzenes; Heterocyclic Fatty Acids; Unsaturated Fatty Acids; Aryl Fluorides; Secondary Alcohols; Enolates; Carboxylic Acids; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>4-phenylpyridine; fluorobenzene; beta-hydroxy acid; hydroxy acid; aryl halide; benzene; pyridine; aryl fluoride; secondary alcohol; carboxylic acid; polyamine; enolate; carboxylic acid derivative; organofluoride; alcohol; organonitrogen compound; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Pitavastatin is used to lower serum levels of total cholesterol, LDL-C, apolipoprotein B, and triglycerides, and raise levels of HDL-C for the treatment of dyslipidemia. </td></tr><tr><th>Pharmacodynamics</th><td>The magnitude of LDL-C reduction by pitavastatin (2 mg and 4 mg) is comparable to atorvastatin (10 mg and 20 mg) and simvastatin (20 mg and 40 mg). It also does not prolong the QTc interval to a clinically significant degree. </td></tr><tr><th>Mechanism of action</th><td>Pitavastatin is lipid-lowering agent that works to control the synthesis of cholesterol via competitive inhibition of the liver enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. As a result, a compensatory increase in LDL-receptor expression can be observed which facilitates an increase LDL catabolism. </td></tr><tr><th>Absorption</th><td>Bioavailability = 51%;
Time to peak, plasma = 1 hour;
Pitavastatin was absorbed in the small intestine but very little in the colon. Cmax decreases by 43% if pitavastatin is taken with a fatty meal but there are no significant changes to AUC or baseline LDL levels compared to fasting state. The Cmax and AUC of pitavastatin did not differ following evening or morning drug administration. </td></tr><tr><th>Volume of distribution</th><td><p>148 L</p></td></tr><tr><th>Protein binding</th><td>&gt;99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Pitavastatin is mainly metabolized by liver. It undergoes glucuronidation by uridine 5-diphosphate glucuronosyl transferases (UGT1A3 and UGT2B7) to form the major circulating metabolite, pitavastatin lactone. 

The cytochrome P450 system has little involvement with the metabolism of pitavastatin. There is some metabolism by CYP2C9 and to a lesser extent, CYP2C8. Studies suggest that concomitant therapy with drugs that are involved with the cytochrome P450 system will not effect the pharmacokinetics of pitavastatin. </p></td></tr><tr><th>Route of elimination</th><td>79% in feces and 15% excreted in urine. </td></tr><tr><th>Half life</th><td>Plasma elimination half-lfie = 12 hours </td></tr><tr><th>Clearance</th><td><p>CL/F (apparent clearance), 4 mg, healthy male Korean subjects = 23.6 L/h</p></td></tr><tr><th>Toxicity</th><td>The most frequent adverse reactions (rate &#8805;2.0% in at least one marketed dose) were myalgia, back pain, diarrhea, constipation and pain in extremity. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9735</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9296</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5135</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9015</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9672</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9101</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7757</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7668</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5634</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6867</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7168</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8695</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6855</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6481</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.837
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9038
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.997
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1821 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.987
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.926
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>1 mg, 2 mg, 4 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6,465,477</td><td>2009-08-03</td><td>2016-12-20</td></tr><tr><td>United States</td><td>5,753,675</td><td>2009-08-03</td><td>2015-05-19</td></tr><tr><td>United States</td><td>5,856,336</td><td>2009-08-03</td><td>2016-01-05</td></tr><tr><td>United States</td><td>7,022,713</td><td>2009-08-03</td><td>2024-02-19</td></tr><tr><td>United States</td><td>5,854,259</td><td>2009-08-03</td><td>2015-12-29</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>water solubility</td><td>Very slightly soluble </td><td>FDA label </td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>3.94e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.75</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.92</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-5</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>4.13</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>4.86</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>90.65</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>115.74</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>43.86</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Shriprakash Dhar <span class="caps">DWIVEDI</span>, Dhimant Jasubhai <span class="caps">PATEL</span>, Alpesh Pravinchandra <span class="caps">SHAH</span>, &#8220;<span class="caps">METHOD</span> <span class="caps">FOR</span> <span class="caps">PREPARATION</span> OF <span class="caps">PITAVASTATIN</span> <span class="caps">AND</span> <span class="caps">ITS</span> <span class="caps">PHARMACEUTICAL</span> <span class="caps">ACCEPTABLE</span> <span class="caps">SALTS</span> <span class="caps">THEREOF</span>.&#8221; U.S. Patent US20120022102, issued January 26, 2012.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20120022102&amp;tbm=pts" target="_blank">US20120022102 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/<span class="caps">FJC</span>.0b013e318256cdf0. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22472908">Pubmed</a></li>
	<li>Jung JA, Noh YH, Jin S, Kim MJ, Kim YH, Jung JA, Lim HS, Bae KS: Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Clin Ther. 2012 Apr;34(4):958-65. doi: 10.1016/j.clinthera.2012.01.026. Epub 2012 Mar 10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22410289">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01862" target="_blank">D01862 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C13334" target="_blank">C13334 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=32020" target="_blank">32020 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201753" target="_blank">CHEMBL1201753 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA142650384" target="_blank">PA142650384 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/livalo-drug.htm" target="_blank">http://www.rxlist.com/livalo-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/ppa/pitavastatin.html" target="_blank">http://www.drugs.com/ppa/pitavastatin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Pitavastatin" target="_blank">Pitavastatin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C10AA08<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C10#C10">C10 &#8212; LIPID MODIFYING AGENTS</a></li><li><a href="/atc/C10A#C10A">C10A &#8212; LIPID MODIFYING AGENTS, PLAIN</a></li><li><a href="/atc/C10AA#C10AA">C10AA &#8212; HMG CoA reductase inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:0608 </li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08860.pdf?1366333044">show</a>(460 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08860.pdf?1366333044">show</a>(116 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Increases serum concentration of pitavastatin and the potential for adverse drug reactions. Avoid concomitant drug therapy.</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased incidence of myotoxicity including rhabdomyolysis during concomitant therapy. The mechanism of this interaction is unclear, it may arise from pharmacodynamic and/or pharmacokinetic interactions. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy. </td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both fenofibrate and pitavastatin via pharmacodynamic synergism. Use alternative therapy. </td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both gemfibrozil and pitavastatin via pharmacodynamic synergism. Use alternative therapy. </td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Lopinavir decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.</td></tr><tr><td><a href="/drugs/DB00627">Niacin</a></td><td>Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both niacin and pitavastatin via pharmacodynamic synergism. Use alternative therapy. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid taking pitavastatin with red yeast rice. May increase risk of myopathy of pitavastatin via pharmacodynamic synergism. Red yeast rice contain monocolin K (similar to lovastatin) </li>
<li>Take with or without food </li></ul></td></tr></tbody></table>